Plain-English translation of NCT06429839 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new medication called nimotuzumab, given alongside chemotherapy and radiation therapy, for patients with advanced esophageal cancer who are elderly or malnourished. Nimotuzumab is a targeted drug that works by blocking a protein that helps cancer cells grow. The goal is to see whether this combination approach can shrink tumors enough to make surgery possible, or to help patients live longer and feel better.
Elderly and malnourished patients with advanced esophageal cancer have few good treatment options and poor outcomes with standard care alone. This trial exists to find out whether adding this medication to chemotherapy and radiation can improve survival and quality of life for this vulnerable group of patients.
You likely qualify if…
You likely don't qualify if…
You would receive the new medication (nimotuzumab) once a week for several weeks, at the same time you receive chemotherapy and radiation therapy directed at your esophageal tumor. After completing this combined treatment, you would have surgery to remove any remaining cancer. Throughout the trial, you would have regular blood tests, scans, and doctor visits to monitor how well the treatment is working and to watch for side effects.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
China